Aggressive characteristics of myeloblasts expressing CD7 in myelodysplastic syndromes
Authors:
- Kiyoyuki OgataKOKiyoyuki Ogata
- 1 February 2009
- journal article
- research article
- Published by Elsevier in Leukemia Research
- Vol. 33 (2) , 326-331
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression dataBlood, 2008
- An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cellsBlood, 2007
- Monocyte Chemoattractant Protein-1 Induces a Novel Transcription Factor That Causes Cardiac Myocyte Apoptosis and Ventricular DysfunctionCirculation Research, 2006
- Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CMLBlood, 2006
- Clinical implications of blast immunophenotypes in myelodysplastic syndromesLeukemia & Lymphoma, 2005
- Identification and Hematopoietic Potential of CD45 − Clonal Cells with Very Immature Phenotype (CD45 − CD34 − CD38 − Lin − ) in Patients with Myelodysplastic SyndromesStem Cells, 2005
- FGF-2 potently induces both proliferation and DSP expression in collagen type I gel cultures of adult incisor immature pulp cellsBiochemical and Biophysical Research Communications, 2004
- CD7 expression by CD34+ cells in CML patients, of prognostic significance?European Journal of Haematology, 2003
- Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndromeBlood, 2002
- Inhibition of lymphocyte proliferation by a monoclonal antibody (RFT2) against CD7Clinical and Experimental Immunology, 1991